Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases

被引:30
|
作者
Lunkes, A
Trottier, Y
Mandel, JL
机构
[1] Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France
[2] Hop Univ Strasbourg, Strasbourg, France
来源
ESSAYS IN BIOCHEMISTRY, VOL 33, 1998 | 1998年 / 33卷
关键词
D O I
10.1042/bse0330149
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
• HD is an autosomal dominant neurodegenerative disorder characterized by involuntary movements, cognitive impairment progressing to dementia, and mood disturbances. The brains of patients show extensive neuronal loss in the striatum, and the cerebral cortex is also affected. • The genetic defect causing HD is an expansion of a CAG repeat encoding a polyglutamine stretch in the target protein, named huntingtin. • The age of onset of HD is inversely correlated with the size of the expansion. • Polyglutamine expansion represents a novel cause of neurodegeneration, which has been shown to be responsible for seven other inherited disorders. • The polyglutamine expansion confers a gain of toxic property to the mutated target proteins. • Molecular and cellular studies of the brains of patients and of mice models of polyglutamine expansion diseases have led to the identification of abnormal intracellular inclusions representing aggregation of the mutated protein. However, the mechanism whereby such polyglutamine expansion leads to selective neuronal dysfunction and death is still puzzling.
引用
收藏
页码:149 / 163
页数:15
相关论文
共 50 条
  • [31] Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation
    Seidel, K.
    Siswanto, S.
    Fredrich, M.
    Bouzrou, M.
    Brunt, E. R.
    van Leeuwen, F. W.
    Kampinga, H. H.
    Korf, H. -W.
    Rueb, U.
    den Dunnen, W. F. A.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (02) : 153 - 166
  • [32] Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes
    Stuitje, Geerte
    van Belzen, Martine J.
    Gardiner, Sarah L.
    van Roon-Mom, Willeke M. C.
    Boogaard, Merel W.
    Tabrizi, Sarah J.
    Roos, Raymund A. C.
    Aziz, N. A.
    BRAIN, 2017, 140
  • [33] Therapeutic advances in Huntington's disease with relevance to other repeat expansion disorders
    Tabrizi, S. J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 28 - 28
  • [34] Polyglutamine expansion diseases: failing to deliver
    Morfini, G
    Pigino, G
    Brady, ST
    TRENDS IN MOLECULAR MEDICINE, 2005, 11 (02) : 64 - 70
  • [35] Management of Huntington's disease manifestations that could have implications for other diseases
    Nance, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S49 - S49
  • [36] On the pathological progression of Huntington's disease - Reply
    Penney, JB
    VonSattel, JP
    MacDonald, ME
    Gusella, JF
    Myers, RH
    ANNALS OF NEUROLOGY, 1998, 44 (01) : 149 - 149
  • [37] Neuro-Cardio Mechanisms in Huntington's Disease and Other Neurodegenerative Disorders
    Critchley, Bethan J.
    Isalan, Mark
    Mielcarek, Michal
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [38] Pcaf Modulates Polyglutamine Pathology in a Drosophila Model of Huntington's Disease
    Bodai, Laszlo
    Pallos, Judit
    Thompson, Leslie Michels
    Marsh, J. Lawrence
    NEURODEGENERATIVE DISEASES, 2012, 9 (02) : 104 - 106
  • [39] Huntington’s disease and other choreas
    N. Quinn
    Anette Schrag
    Journal of Neurology, 1998, 245 : 709 - 716
  • [40] Huntington's disease and other choreas
    Quinn, N
    Schrag, A
    JOURNAL OF NEUROLOGY, 1998, 245 (11) : 709 - 716